Should retreat below $3 in the coming weeks. Nexavar is much more than just serious competition, and PI-88 does not have anything close to the efficacy that Nexavar has demonstrated as the best-in-class treatment regime.
The sp may well go into freefall, as the viability of their drug development program is brought into question.
